Gordon Phillips to Antineoplastic Agents
This is a "connection" page, showing publications Gordon Phillips has written about Antineoplastic Agents.
Connection Strength
0.135
-
Keller SF, Kelly JL, Sensenig E, Andreozzi J, Oliva J, Rich L, Constine L, Becker M, Phillips G, Liesveld J, Fisher RI, Bernstein SH, Friedberg JW. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. Biol Blood Marrow Transplant. 2012 Apr; 18(4):640-7.
Score: 0.061
-
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.
Score: 0.049
-
Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma. 2012 May; 53(5):830-5.
Score: 0.016
-
Bolaños-Meade J, Phillips GL, Badros A. Tandem transplantation in multiple myeloma. Oncology (Williston Park). 2003 Mar; 17(3):389-98; discussion 398-400, 405-7.
Score: 0.009